ClinicalTrials.gg
Approved for marketingNCT06360237Updated Dec 27, 2024

Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)

An expanded access record providing Olezarsen in Familial Chylomicronemia Syndrome, sponsored by Ionis Pharmaceuticals, Inc.. Approved for marketing at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by Ionis Pharmaceuticals, Inc. · Expanded access

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Individual patients
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the Expanded Access Program is to provide pre-approval access of olezarsen to eligible patients with Familial Chylomicronemia Syndrome (FCS).

Read the detailed description

The Expanded Access Program (EAP) is intended to provide pre-approval access to olezarsen for eligible patients with FCS who have limited or no available treatment options. This program is open in the United States and operates under the individual patient (also referred to as single patient) IND expanded access route in which the patient's treating physician serves as the sponsor. Expanded access requests must be from the patient's treating physicians and submitted according to the instructions at https://www.ionispharma.com/patients/expanded-access-policy/

02

Conditions studied

  • Familial Chylomicronemia Syndrome

Keywords

  • Familial Chylomicronemia
  • Familial Lipoprotein Lipase Deficiency
  • Hyperlipoproteinemias
  • Familial Hyperlipoproteinemia Type 1
  • Hyperlipoproteinemia Type 1
  • Hyperchylomicronemia, Familial
  • Lipoprotein Lipase Deficiency, Familial
  • Hyperlipidemias
  • Dyslipidemias
  • Lipid Metabolism Disorders
  • Lipid Metabolism, Inborn Errors
  • Metabolic Diseases
  • Metabolism, Inborn Errors
  • Genetic Diseases, Inborn
03

In context

Hyperlipoproteinemia Type I

21 studies on the registry are indexed under Hyperlipoproteinemia Type I; 3 are open to participants now.

Browse Hyperlipoproteinemia Type I studies →

Lead sponsor

Ionis Pharmaceuticals, Inc. is the lead sponsor of 118 studies on the registry; 10 are open to participants now.

Of its 49 completed or terminated interventional studies of FDA-regulated products, 22 (45%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a diagnosis of FCS as determined by the sponsoring physician. Ionis will review each application to determine eligibility based on documentation of validated genetic or clinical diagnosis.

    o Documented loss of function mutations (homozygous, compound / double heterozygous) in genes such as LPL, GPIHBP1, APOA5, APOC2 or LMF1) or clinically validated diagnosis of FCS.

  • Resides in and is a resident of the United States.
  • Willing to follow a diet comprising ≤20 g fat per day.

Exclusion criteria

Exclusion Criteria:

  • Has any new or worsening of existing conditions which, in the opinion of the physician, would make the patient unsuitable for treatment with olezarsen.
  • Olezarsen naïve patients with baseline count \<100x109/L at qualification.
  • Estimated (eGFR) \<30 mL/min/1.73 m2.
  • Secondary factors are the cause of triglyceride elevations.
  • Is currently hospitalized in an acute emergency setting.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Access details

Study type
Expanded access
Access type
Individual patients

Available treatment

  • Olezarsen 80 mg administered once monthly by subcutaneous (SC) injections in the abdomen, thigh, or upper arm.

    Also known as: ISIS-678354

06

Where to request access

1 site
  • Expanded Access Site
    Carlsbad, California 92010, United States
07

References and documents

Related links

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06360237
Responsible party
Sponsor
First posted
Apr 11, 2024
Last update
Dec 27, 2024
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion